Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

THERE’S been an “alarming” increase in HIV infections among straight women, a new report warns. It comes as sexual health ...

But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...

Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...